Talazoparib induces DNA damage and can upregulate immune pathways including STING/type I IFN in tumor cells rationale for combinations with ICI, especially in HR-deficient tumors; effectiveness associated with context (BRCA/HR defects). The gene discussed is STING1; the disease is neoplasm.